Sleep apnoea, particularly when it persists for extended periods, is far more than a mere interruption to rest. For many sufferers, it evolves into a chronic condition with profound and often underdiagnosed consequences for cardiovascular health, metabolic function, and cognitive performance. The condition—where breathing repeatedly stops and restarts during sleep—affects an estimated 1 in 5 adults in the UK, yet many remain undiagnosed. Untreated, it can escalate into life-threatening complications, making early intervention critical. Research suggests that individuals with severe obstructive sleep apnoea (OSA) have a two to threefold increased risk of developing hypertension, and studies link it to a 40% higher likelihood of cardiovascular events, including heart attacks and strokes. The condition also disrupts deep sleep cycles, impairing the body’s ability to repair tissues and regulate hormones, which can contribute to conditions like type 2 diabetes and obesity.
One of the most alarming long-term effects of untreated sleep apnoea is its association with cognitive decline. A 2021 study published in The Lancet Neurology found that patients with moderate to severe OSA exhibited accelerated cognitive decline comparable to that of individuals aged five years older. The disruption to sleep architecture—particularly the loss of rapid eye movement (REM) sleep—has been linked to memory deficits, reduced processing speed, and an increased risk of neurodegenerative diseases, including Alzheimer’s. Even mild cases can impair executive function and emotional regulation, making it difficult for individuals to manage daily tasks or maintain mental well-being. The link between sleep apnoea and dementia is not yet fully understood, but experts warn that addressing the condition early could help mitigate some of these risks.
Beyond neurological and cardiovascular risks, long-duration sleep apnoea has been connected to a range of metabolic disturbances. A 2022 meta-analysis in JAMA Internal Medicine revealed that OSA is independently associated with insulin resistance, a precursor to type 2 diabetes. The condition disrupts the body’s glucose metabolism, leading to elevated fasting glucose levels and reduced sensitivity to insulin. Additionally, the repeated awakenings caused by apnoea events trigger the release of stress hormones like cortisol, which can further exacerbate metabolic dysfunction. Obesity, a common comorbidity, amplifies these effects, creating a vicious cycle where poor sleep worsens weight gain and vice versa. For those with pre-existing metabolic conditions, OSA can act as a tipping point, accelerating disease progression.
Diagnosis remains a challenge for many, partly due to the lack of widespread screening and the subjective nature of symptoms. Symptoms such as excessive daytime sleepiness, morning headaches, and snoring are often dismissed as minor inconveniences rather than warning signs. However, advances in home sleep testing—including continuous positive airway pressure (CPAP) devices and portable monitoring—have made diagnosis more accessible. The NHS now recommends that individuals with persistent snoring, gasping during sleep, or unexplained daytime fatigue be referred for a sleep study. Early intervention, whether through lifestyle changes, dental appliances, or CPAP therapy, can significantly reduce long-term risks. For example, studies have shown that CPAP treatment reduces blood pressure by an average of 10 mmHg within six months and lowers the risk of stroke by up to 30% over a decade.
Yet, despite these benefits, adherence to treatment remains low. A 2023 survey by the British Sleep Society found that only about 40% of patients who receive a CPAP prescription continue using it regularly. Barriers include discomfort with the device, social stigma, and the inconvenience of wearing it nightly. Addressing these challenges requires a multifaceted approach, including education campaigns to normalise sleep health, financial support for affordable devices, and mental health support for those struggling with adherence. Without such efforts, the long-term toll of untreated sleep apnoea will continue to grow, leaving many at risk of preventable complications.
For those who suspect they may have sleep apnoea, consulting a healthcare professional is the first step. The learn more about the condition’s symptoms, diagnostic processes, and treatment options can help clarify next steps. Early intervention is key to protecting both physical and mental health, ensuring that sleep apnoea does not become a silent but devastating force in the lives of those affected.
- Approximately 1 in 5 adults in the UK has sleep apnoea, yet only about 30% are formally diagnosed.
- Individuals with severe OSA have a 40% higher risk of developing hypertension and a two to threefold increased risk of cardiovascular events.
- Sleep apnoea is linked to a 50% higher likelihood of developing type 2 diabetes and insulin resistance.
- Untreated OSA accelerates cognitive decline, with some studies showing a cognitive decline equivalent to ageing five years faster.
- Only about 40% of patients who receive CPAP therapy continue using it regularly due to adherence challenges.
